Highlights on the Development, Related Patents, and Prospects of Lenacapavir: The First-in-Class HIV-1 Capsid Inhibitor for the Treatment of Multi-Drug-Resistant HIV-1 Infection

The multidrug-resistant (MDR) human immunodeficiency virus 1 (HIV-1) infection is an unmet medical need. HIV-1 capsid plays an important role at different stages of the HIV-1 replication cycle and is an attractive drug target for developing therapies against MDR HIV-1 infection. Lenacapavir (LEN) is...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Tafadzwa Dzinamarira, Mazen Almehmadi, Ahad Amer Alsaiari, Mamdouh Allahyani, Abdulelah Aljuaid, Abdulaziz Alsharif, Abida Khan, Mehnaz Kamal, Ali A. Rabaan, Amal H. Alfaraj, Bashayer M. AlShehail, Nouf Alotaibi, Shams M. AlShehail, Mohd Imran
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	MDPI AG 2023-05-01
Saila:	Medicina
Gaiak:	Lenacapavir Sunlenca GS-6207 HIV-1 capsid patent prospects
Sarrera elektronikoa:	https://www.mdpi.com/1648-9144/59/6/1041
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!